세계의 암치료용 유전체학 시장 규모, 점유율, 동향 분석 : 용도별, 제품별, 기술별, 지역별, 전망과 예측(2024-2031년)

The Global Genomics In Cancer Care Market size is expected to reach $53.5 billion by 2031, rising at a market growth of 15.7% CAGR during the forecast period.

High-throughput capabilities are provided by microarrays, which allow for the simultaneous analysis of thousands of transcripts in a single experiment. This extensive data collection is crucial for understanding cancer's complex genetic and molecular landscapes, leading to increased demand for microarray technologies in research and clinical applications. Microarrays enable comprehensive gene expression profiling, which helps identify differentially expressed cancer-associated genes. By providing a broad overview of gene activity, microarrays support discovering biomarkers, elucidating cancer mechanisms, and developing new therapeutic targets. Thus, the microarrays segment held 21% revenue share in the genomics in cancer care market.

The major strategies followed by the market participants are Acquisition as the key developmental strategy to keep pace with the changing demands of end users. For instance, In 2023, January, Agilent Technologies acquired Avida Biomed, a cancer care solutions provider. The acquisition enhances its SureSelect portfolio with advanced target enrichment workflows for next-generation sequencing. Additionally, In 2021, June, PerkinElmer, now known as Revvity, Inc., took over Sirion Biotech, a German biotech company. The acquisition enhances Perkinelmer's cell and gene therapy offerings.

Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd. is the forerunners in the Genomics In Cancer Care Market. Companies such as Abbott Laboratories, Danaher Corporation (Beckman Coulter, Inc.), GE HealthCare Technologies, Inc. are some of the key innovators in Genomics In Cancer Care Market.

COVID-19 Impact Analysis

Budget cuts and reallocating funds towards COVID-19 response efforts resulted in reduced investment in genomic research and development. Many clinical trials for genomic-based cancer therapies were paused or delayed during the pandemic. Recruitment of participants was hindered, and trial timelines were extended, affecting the development and availability of new genomic treatments. Thus, the COVID-19 pandemic had a negative impact on the market.

Market Growth Factors

A better grasp of cancer genomics allows for developing personalized medicine approaches. By analyzing a patient's unique genetic makeup, healthcare providers can tailor treatment plans specifically to the individual's cancer type and genetic profile. This personalized approach improves treatment efficacy and minimizes adverse effects, leading to a growing demand for genomic-based treatments.

Additionally, the increased focus on genomic research drives market growth by fostering the development of new genomic technologies and therapies. Thus, the rise in cancer incidence and prevalence is driving the growth of the market.

Market Restraining Factors

High costs of genomic testing can exacerbate disparities in healthcare access, particularly in low- and middle-income regions or among underserved populations. These disparities can result in unequal access to advanced genomic technologies and personalized treatments, affecting the overall market growth and hindering equitable cancer care. Hence, the high costs of genomic testing impede the market's growth.

Application Outlook

On the basis of application, the market is segmented into diagnostics, personalized medicine, drug discovery & development, and research. The diagnostics segment recorded 39% revenue share in the genomics in cancer care market in 2023. Genomic diagnostics are crucial in early detection and accurate cancer diagnosis.

Product Outlook

Based on product, the market is divided into instruments, consumables, and services. The services segment attained 21% revenue share in the genomics in cancer care market in 2023. As genomic technologies advance, the complexity of analyzing and interpreting genomic data increases.

Technology Outlook

By technology, the market is divided into genome sequencing, PCR, microarrays, nuclei acid extraction and purification, and others. In 2023, the PCR segment registered 32% revenue share in the genomics in cancer care market. PCR is known for its high sensitivity and specificity, which are crucial for accurately detecting and quantifying cancer-related genetic material.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2023, the Asia Pacific region generated 26% revenue share in the genomics in cancer care market. The Asia-Pacific region is experiencing a rising incidence of cancer due to factors such as population growth, aging demographics, and changes in lifestyle and environmental exposures.

Market Competition and Attributes

The Genomics in Cancer Care market is fiercely competitive, driven by rapid technological advancements and the increasing demand for personalized medicine. Key attributes include innovative genomic testing techniques, comprehensive data analytics capabilities, and robust bioinformatics solutions. Companies strive to differentiate through superior accuracy in cancer diagnostics, treatment selection, and monitoring. Market leaders focus on integrating multi-omic data to enhance therapeutic outcomes, while regulatory compliance and data privacy remain critical concerns.

Recent Strategies Deployed in the Market

• Aug-2024: Beckman Coulter Life Sciences released the Illumina TruSight Oncology 500 DNA/RNA assa, an automated solution for oncology research on the Biomek NGeniuS System. This tool accelerates genomic profiling of tumor samples, handling up to 24 libraries per batch with reduced costs and faster results.
• Apr-2024: Bio-Rad Laboratories partnered with Allegheny Health Network to research the use of Bio-Rad's Droplet Digital PCR (ddPCR) technology for monitoring molecular residual disease (MRD) in solid tumors. This partnership would enhance sensitivity and precision in detecting MRD, potentially improving patient outcomes through earlier and more accurate monitoring.
• Apr-2024: Bio-Rad Laboratories released the ddPLEX ESR1 Mutation Detection Kit, a highly sensitive multiplexed digital PCR assay for detecting seven ESR1 mutations with 0.01% sensitivity. Compatible with the QX600 System, it provides rapid, simultaneous results from ctDNA or FFPE samples, enhancing oncology research and patient monitoring.
• Oc-2023: F. Hoffmann-La Roche Ltd teamed up with AWS, a cloud computing company, to integrate AI-powered tools into its navify Digital Pathology platform. This partnership enhanced breast and prostate cancer diagnosis by improving accuracy, efficiency, and turnaround time in pathology labs, leveraging cloud infrastructure for scalability and security.

List of Key Companies Profiled

• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation (Beckman Coulter, Inc.)
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• GE HealthCare Technologies, Inc.
• Quest Diagnostics Incorporated
• Revvity, Inc.
• Eurofins Scientific SE
• Hologic, Inc.

Global Genomics In Cancer Care Market Report Segmentation

By Application

• Diagnostics
• Personalized Medicine
• Drug Discovery & Development
• Research

By Product

• Instruments
• Consumables
• Services

By Technology

• PCR
• Genome Sequencing
• Microarrays
• Nuclei Acid Extraction & Purification
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Genomics In Cancer Care Market, by Application
  • 1.4.2 Global Genomics In Cancer Care Market, by Product
  • 1.4.3 Global Genomics In Cancer Care Market, by Technology
  • 1.4.4 Global Genomics In Cancer Care Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges

Chapter 4. Competition Analysis - Global

• 4.1 KBV Cardinal Matrix
• 4.2 Recent Industry Wide Strategic Developments
  • 4.2.1 Partnerships, Collaborations and Agreements
  • 4.2.2 Product Launches and Product Expansions
  • 4.2.3 Acquisition and Mergers
• 4.3 Market Share Analysis, 2023
• 4.4 Top Winning Strategies
  • 4.4.1 Key Leading Strategies: Percentage Distribution (2020-2024)
  • 4.4.2 Key Strategic Move: (Mergers and Acquisitions: 2021, Jan - 2023, Jan) Leading Players
• 4.5 Porter Five Forces Analysis

Chapter 5. Global Genomics In Cancer Care Market by Application

• 5.1 Global Diagnostics Market by Region
• 5.2 Global Personalized Medicine Market by Region
• 5.3 Global Drug Discovery & Development Market by Region
• 5.4 Global Research Market by Region

Chapter 6. Global Genomics In Cancer Care Market by Product

• 6.1 Global Instruments Market by Region
• 6.2 Global Consumables Market by Region
• 6.3 Global Services Market by Region

Chapter 7. Global Genomics In Cancer Care Market by Technology

• 7.1 Global PCR Market by Region
• 7.2 Global Genome Sequencing Market by Region
• 7.3 Global Microarrays Market by Region
• 7.4 Global Nuclei Acid Extraction & Purification Market by Region
• 7.5 Global Others Market by Region

Chapter 8. Global Genomics In Cancer Care Market by Region

• 8.1 North America Genomics In Cancer Care Market
  • 8.1.1 North America Genomics In Cancer Care Market by Application
    • 8.1.1.1 North America Diagnostics Market by Country
    • 8.1.1.2 North America Personalized Medicine Market by Country
    • 8.1.1.3 North America Drug Discovery & Development Market by Country
    • 8.1.1.4 North America Research Market by Country
  • 8.1.2 North America Genomics In Cancer Care Market by Product
    • 8.1.2.1 North America Instruments Market by Country
    • 8.1.2.2 North America Consumables Market by Country
    • 8.1.2.3 North America Services Market by Country
  • 8.1.3 North America Genomics In Cancer Care Market by Technology
    • 8.1.3.1 North America PCR Market by Country
    • 8.1.3.2 North America Genome Sequencing Market by Country
    • 8.1.3.3 North America Microarrays Market by Country
    • 8.1.3.4 North America Nuclei Acid Extraction & Purification Market by Country
    • 8.1.3.5 North America Others Market by Country
  • 8.1.4 North America Genomics In Cancer Care Market by Country
    • 8.1.4.1 US Genomics In Cancer Care Market
      • 8.1.4.1.1 US Genomics In Cancer Care Market by Application
      • 8.1.4.1.2 US Genomics In Cancer Care Market by Product
      • 8.1.4.1.3 US Genomics In Cancer Care Market by Technology
    • 8.1.4.2 Canada Genomics In Cancer Care Market
      • 8.1.4.2.1 Canada Genomics In Cancer Care Market by Application
      • 8.1.4.2.2 Canada Genomics In Cancer Care Market by Product
      • 8.1.4.2.3 Canada Genomics In Cancer Care Market by Technology
    • 8.1.4.3 Mexico Genomics In Cancer Care Market
      • 8.1.4.3.1 Mexico Genomics In Cancer Care Market by Application
      • 8.1.4.3.2 Mexico Genomics In Cancer Care Market by Product
      • 8.1.4.3.3 Mexico Genomics In Cancer Care Market by Technology
    • 8.1.4.4 Rest of North America Genomics In Cancer Care Market
      • 8.1.4.4.1 Rest of North America Genomics In Cancer Care Market by Application
      • 8.1.4.4.2 Rest of North America Genomics In Cancer Care Market by Product
      • 8.1.4.4.3 Rest of North America Genomics In Cancer Care Market by Technology
• 8.2 Europe Genomics In Cancer Care Market
  • 8.2.1 Europe Genomics In Cancer Care Market by Application
    • 8.2.1.1 Europe Diagnostics Market by Country
    • 8.2.1.2 Europe Personalized Medicine Market by Country
    • 8.2.1.3 Europe Drug Discovery & Development Market by Country
    • 8.2.1.4 Europe Research Market by Country
  • 8.2.2 Europe Genomics In Cancer Care Market by Product
    • 8.2.2.1 Europe Instruments Market by Country
    • 8.2.2.2 Europe Consumables Market by Country
    • 8.2.2.3 Europe Services Market by Country
  • 8.2.3 Europe Genomics In Cancer Care Market by Technology
    • 8.2.3.1 Europe PCR Market by Country
    • 8.2.3.2 Europe Genome Sequencing Market by Country
    • 8.2.3.3 Europe Microarrays Market by Country
    • 8.2.3.4 Europe Nuclei Acid Extraction & Purification Market by Country
    • 8.2.3.5 Europe Others Market by Country
  • 8.2.4 Europe Genomics In Cancer Care Market by Country
    • 8.2.4.1 Germany Genomics In Cancer Care Market
      • 8.2.4.1.1 Germany Genomics In Cancer Care Market by Application
      • 8.2.4.1.2 Germany Genomics In Cancer Care Market by Product
      • 8.2.4.1.3 Germany Genomics In Cancer Care Market by Technology
    • 8.2.4.2 UK Genomics In Cancer Care Market
      • 8.2.4.2.1 UK Genomics In Cancer Care Market by Application
      • 8.2.4.2.2 UK Genomics In Cancer Care Market by Product
      • 8.2.4.2.3 UK Genomics In Cancer Care Market by Technology
    • 8.2.4.3 France Genomics In Cancer Care Market
      • 8.2.4.3.1 France Genomics In Cancer Care Market by Application
      • 8.2.4.3.2 France Genomics In Cancer Care Market by Product
      • 8.2.4.3.3 France Genomics In Cancer Care Market by Technology
    • 8.2.4.4 Russia Genomics In Cancer Care Market
      • 8.2.4.4.1 Russia Genomics In Cancer Care Market by Application
      • 8.2.4.4.2 Russia Genomics In Cancer Care Market by Product
      • 8.2.4.4.3 Russia Genomics In Cancer Care Market by Technology
    • 8.2.4.5 Spain Genomics In Cancer Care Market
      • 8.2.4.5.1 Spain Genomics In Cancer Care Market by Application
      • 8.2.4.5.2 Spain Genomics In Cancer Care Market by Product
      • 8.2.4.5.3 Spain Genomics In Cancer Care Market by Technology
    • 8.2.4.6 Italy Genomics In Cancer Care Market
      • 8.2.4.6.1 Italy Genomics In Cancer Care Market by Application
      • 8.2.4.6.2 Italy Genomics In Cancer Care Market by Product
      • 8.2.4.6.3 Italy Genomics In Cancer Care Market by Technology
    • 8.2.4.7 Rest of Europe Genomics In Cancer Care Market
      • 8.2.4.7.1 Rest of Europe Genomics In Cancer Care Market by Application
      • 8.2.4.7.2 Rest of Europe Genomics In Cancer Care Market by Product
      • 8.2.4.7.3 Rest of Europe Genomics In Cancer Care Market by Technology
• 8.3 Asia Pacific Genomics In Cancer Care Market
  • 8.3.1 Asia Pacific Genomics In Cancer Care Market by Application
    • 8.3.1.1 Asia Pacific Diagnostics Market by Country
    • 8.3.1.2 Asia Pacific Personalized Medicine Market by Country
    • 8.3.1.3 Asia Pacific Drug Discovery & Development Market by Country
    • 8.3.1.4 Asia Pacific Research Market by Country
  • 8.3.2 Asia Pacific Genomics In Cancer Care Market by Product
    • 8.3.2.1 Asia Pacific Instruments Market by Country
    • 8.3.2.2 Asia Pacific Consumables Market by Country
    • 8.3.2.3 Asia Pacific Services Market by Country
  • 8.3.3 Asia Pacific Genomics In Cancer Care Market by Technology
    • 8.3.3.1 Asia Pacific PCR Market by Country
    • 8.3.3.2 Asia Pacific Genome Sequencing Market by Country
    • 8.3.3.3 Asia Pacific Microarrays Market by Country
    • 8.3.3.4 Asia Pacific Nuclei Acid Extraction & Purification Market by Country
    • 8.3.3.5 Asia Pacific Others Market by Country
  • 8.3.4 Asia Pacific Genomics In Cancer Care Market by Country
    • 8.3.4.1 China Genomics In Cancer Care Market
      • 8.3.4.1.1 China Genomics In Cancer Care Market by Application
      • 8.3.4.1.2 China Genomics In Cancer Care Market by Product
      • 8.3.4.1.3 China Genomics In Cancer Care Market by Technology
    • 8.3.4.2 Japan Genomics In Cancer Care Market
      • 8.3.4.2.1 Japan Genomics In Cancer Care Market by Application
      • 8.3.4.2.2 Japan Genomics In Cancer Care Market by Product
      • 8.3.4.2.3 Japan Genomics In Cancer Care Market by Technology
    • 8.3.4.3 India Genomics In Cancer Care Market
      • 8.3.4.3.1 India Genomics In Cancer Care Market by Application
      • 8.3.4.3.2 India Genomics In Cancer Care Market by Product
      • 8.3.4.3.3 India Genomics In Cancer Care Market by Technology
    • 8.3.4.4 South Korea Genomics In Cancer Care Market
      • 8.3.4.4.1 South Korea Genomics In Cancer Care Market by Application
      • 8.3.4.4.2 South Korea Genomics In Cancer Care Market by Product
      • 8.3.4.4.3 South Korea Genomics In Cancer Care Market by Technology
    • 8.3.4.5 Singapore Genomics In Cancer Care Market
      • 8.3.4.5.1 Singapore Genomics In Cancer Care Market by Application
      • 8.3.4.5.2 Singapore Genomics In Cancer Care Market by Product
      • 8.3.4.5.3 Singapore Genomics In Cancer Care Market by Technology
    • 8.3.4.6 Malaysia Genomics In Cancer Care Market
      • 8.3.4.6.1 Malaysia Genomics In Cancer Care Market by Application
      • 8.3.4.6.2 Malaysia Genomics In Cancer Care Market by Product
      • 8.3.4.6.3 Malaysia Genomics In Cancer Care Market by Technology
    • 8.3.4.7 Rest of Asia Pacific Genomics In Cancer Care Market
      • 8.3.4.7.1 Rest of Asia Pacific Genomics In Cancer Care Market by Application
      • 8.3.4.7.2 Rest of Asia Pacific Genomics In Cancer Care Market by Product
      • 8.3.4.7.3 Rest of Asia Pacific Genomics In Cancer Care Market by Technology
• 8.4 LAMEA Genomics In Cancer Care Market
  • 8.4.1 LAMEA Genomics In Cancer Care Market by Application
    • 8.4.1.1 LAMEA Diagnostics Market by Country
    • 8.4.1.2 LAMEA Personalized Medicine Market by Country
    • 8.4.1.3 LAMEA Drug Discovery & Development Market by Country
    • 8.4.1.4 LAMEA Research Market by Country
  • 8.4.2 LAMEA Genomics In Cancer Care Market by Product
    • 8.4.2.1 LAMEA Instruments Market by Country
    • 8.4.2.2 LAMEA Consumables Market by Country
    • 8.4.2.3 LAMEA Services Market by Country
  • 8.4.3 LAMEA Genomics In Cancer Care Market by Technology
    • 8.4.3.1 LAMEA PCR Market by Country
    • 8.4.3.2 LAMEA Genome Sequencing Market by Country
    • 8.4.3.3 LAMEA Microarrays Market by Country
    • 8.4.3.4 LAMEA Nuclei Acid Extraction & Purification Market by Country
    • 8.4.3.5 LAMEA Others Market by Country
  • 8.4.4 LAMEA Genomics In Cancer Care Market by Country
    • 8.4.4.1 Brazil Genomics In Cancer Care Market
      • 8.4.4.1.1 Brazil Genomics In Cancer Care Market by Application
      • 8.4.4.1.2 Brazil Genomics In Cancer Care Market by Product
      • 8.4.4.1.3 Brazil Genomics In Cancer Care Market by Technology
    • 8.4.4.2 Argentina Genomics In Cancer Care Market
      • 8.4.4.2.1 Argentina Genomics In Cancer Care Market by Application
      • 8.4.4.2.2 Argentina Genomics In Cancer Care Market by Product
      • 8.4.4.2.3 Argentina Genomics In Cancer Care Market by Technology
    • 8.4.4.3 UAE Genomics In Cancer Care Market
      • 8.4.4.3.1 UAE Genomics In Cancer Care Market by Application
      • 8.4.4.3.2 UAE Genomics In Cancer Care Market by Product
      • 8.4.4.3.3 UAE Genomics In Cancer Care Market by Technology
    • 8.4.4.4 Saudi Arabia Genomics In Cancer Care Market
      • 8.4.4.4.1 Saudi Arabia Genomics In Cancer Care Market by Application
      • 8.4.4.4.2 Saudi Arabia Genomics In Cancer Care Market by Product
      • 8.4.4.4.3 Saudi Arabia Genomics In Cancer Care Market by Technology
    • 8.4.4.5 South Africa Genomics In Cancer Care Market
      • 8.4.4.5.1 South Africa Genomics In Cancer Care Market by Application
      • 8.4.4.5.2 South Africa Genomics In Cancer Care Market by Product
      • 8.4.4.5.3 South Africa Genomics In Cancer Care Market by Technology
    • 8.4.4.6 Nigeria Genomics In Cancer Care Market
      • 8.4.4.6.1 Nigeria Genomics In Cancer Care Market by Application
      • 8.4.4.6.2 Nigeria Genomics In Cancer Care Market by Product
      • 8.4.4.6.3 Nigeria Genomics In Cancer Care Market by Technology
    • 8.4.4.7 Rest of LAMEA Genomics In Cancer Care Market
      • 8.4.4.7.1 Rest of LAMEA Genomics In Cancer Care Market by Application
      • 8.4.4.7.2 Rest of LAMEA Genomics In Cancer Care Market by Product
      • 8.4.4.7.3 Rest of LAMEA Genomics In Cancer Care Market by Technology

Chapter 9. Company Profiles

• 9.1 Agilent Technologies, Inc.
  • 9.1.1 Company Overview
  • 9.1.2 Financial Analysis
  • 9.1.3 Segmental and Regional Analysis
  • 9.1.4 Research & Development Expense
  • 9.1.5 Recent strategies and developments:
    • 9.1.5.1 Acquisition and Mergers:
  • 9.1.6 SWOT Analysis
• 9.2 F. Hoffmann-La Roche Ltd.
  • 9.2.1 Company Overview
  • 9.2.2 Financial Analysis
  • 9.2.3 Segmental and Regional Analysis
  • 9.2.4 Research & Development Expense
  • 9.2.5 Recent strategies and developments:
    • 9.2.5.1 Partnerships, Collaborations, and Agreements:
    • 9.2.5.2 Product Launches and Product Expansions:
  • 9.2.6 SWOT Analysis
• 9.3 Danaher Corporation (Beckman Coulter, Inc.)
  • 9.3.1 Company Overview
  • 9.3.2 Financial Analysis
  • 9.3.3 Segmental and Regional Analysis
  • 9.3.4 Research & Development Expense
  • 9.3.5 Recent strategies and developments:
    • 9.3.5.1 Partnerships, Collaborations, and Agreements:
  • 9.3.6 SWOT Analysis
• 9.4 Abbott Laboratories
  • 9.4.1 Company Overview
  • 9.4.2 Financial Analysis
  • 9.4.3 Segmental and Regional Analysis
  • 9.4.4 Research & Development Expense
  • 9.4.5 SWOT Analysis
• 9.5 Bio-Rad laboratories, Inc.
  • 9.5.1 Company Overview
  • 9.5.2 Financial Analysis
  • 9.5.3 Segmental and Regional Analysis
  • 9.5.4 Research & Development Expenses
  • 9.5.5 Recent strategies and developments:
    • 9.5.5.1 Partnerships, Collaborations, and Agreements:
    • 9.5.5.2 Product Launches and Product Expansions:
  • 9.5.6 SWOT Analysis
• 9.6 GE HealthCare Technologies, Inc.
  • 9.6.1 Company Overview
  • 9.6.2 Financial Analysis
  • 9.6.3 Segmental and Regional Analysis
  • 9.6.4 Research & Development Expenses
  • 9.6.5 Recent strategies and developments:
    • 9.6.5.1 Partnerships, Collaborations, and Agreements:
  • 9.6.6 SWOT Analysis
• 9.7 Quest Diagnostics Incorporated
  • 9.7.1 Company Overview
  • 9.7.2 Financial Analysis
  • 9.7.3 Segmental Analysis
  • 9.7.4 SWOT Analysis
• 9.8 Revvity, Inc.
  • 9.8.1 Company Overview
  • 9.8.2 Financial Analysis
  • 9.8.3 Segmental and Regional Analysis
  • 9.8.4 Research & Development Expenses
  • 9.8.5 Recent strategies and developments:
    • 9.8.5.1 Acquisition and Mergers:
  • 9.8.6 SWOT Analysis
• 9.9 Eurofins Scientific SE
  • 9.9.1 Company Overview
  • 9.9.2 Financial Analysis
  • 9.9.3 Regional Analysis
  • 9.9.4 SWOT Analysis
• 9.10. Hologic, Inc.
  • 9.10.1 Company Overview
  • 9.10.2 Financial Analysis
  • 9.10.3 Segmental and Regional Analysis
  • 9.10.4 Research & Development Expenses
  • 9.10.5 Recent strategies and developments:
    • 9.10.5.1 Acquisition and Mergers:
  • 9.10.6 SWOT Analysis

Chapter 10. Winning Imperatives for Genomics In Cancer Care Market